Particularly, PGRN indicated a poor prognosis in tumors mostly associated with metabolic syndrome such as breast cancer [10, 12], colorectal cancer [13], gallbladder cancer [9], bladder cancer [14], and prostate cancer [15]. This evidence concerns the gene GRN and Familial prostate cancer.